Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma

Hae Su Kim; Ji Yun Lee; Sung Hee Lim; Keunchil Park; Jong-Mu Sun; Young Hyeh Ko; Chung-Hwan Baek; Young-ik Son; Han Sin Jeong; Yong Chan Ahn; Min-Young Lee; Mineui Hong; Myung-Ju Ahn

doi:10.4143/crt.2015.249

Articles

Page Path: HOME > Cancer Res Treat > Volume 48(2); 2016 > Article

Original Article Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma: Hae Su Kim, MD¹, Ji Yun Lee, MD¹, Sung Hee Lim, MD¹, Keunchil Park, MD¹, Jong-Mu Sun, MD¹, Young Hyeh Ko, MD², Chung-Hwan Baek, MD³, Young-ik Son, MD³, Han Sin Jeong, MD³, Yong Chan Ahn, MD⁴, Min-Young Lee, MD⁵, Mineui Hong, MD⁶, Myung-Ju Ahn, MD, PhD^1,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2016;48(2):527-536.
DOI: https://doi.org/10.4143/crt.2015.249
Published online: September 15, 2015

¹Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

²Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

³Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

⁴Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

⁵Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea

⁶Department of Pathology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea

Correspondence: Myung-Ju Ahn, MD, PhD Division of Hematology-Oncology Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Tel: 82-2-3410-3438 Fax: 82-2-3410-1754 E-mail: silkahn@skku.edu

• Received: July 13, 2015 • Accepted: August 13, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

17,528 Views
347 Download
111 Web of Science
104 Crossref
113 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Oropharyngeal squamous cell carcinoma (OSCC) has been recognized as an immunosuppressive disease. Various mechanisms have been proposed for immune escape, including dysregulation of immune checkpoints such as the PD-1:PD-L1 pathway. We investigated the expression of programmed cell death-ligand 1 (PD-L1) in HPV-negative and HPV-positive OSCC to determine its prevalence and prognostic relevance.
Materials and Methods
Using immunohistochemistry, 133 cases of OSCC were evaluated for expression of PD-L1. Formalin-fixed paraffin-embedded tumor samples were stained with monoclonal antibody (clone 5H1) to PD-L1. PD-L1 positivity was defined as membrane staining in ≥20% of tumor cells. Correlations between PD-L1 expression and HPV status and survival parameters were analyzed.
Results
Of the 133 patients, 68% showed PD-L1 expression, and 67% of patients were positive for p16 expression by immunohistochemistry. No significant difference in PD-L1 expression was observed between HPV(-) and HPV(+) tumors (61% vs. 71%, p=0.274). No significant difference in age, gender, smoking history, location of tumor origin, or stage was observed according to PD-L1 status. With a median follow-up period of 44 months, older age (≥65) (p=0.017) and T3-4 stage (p<0.001) were associated with poor overall survival (OS), whereas PD-L1 expression did not affect OS in univariate and multivariate analysis.
Conclusion
PD-L1 expression was observed in the majority of OSCC patients regardless of HPV status. Further large prospective studies are required to determine the role of PD-L1 expression as a prognostic or predictive biomarker, and clinical studies of immune checkpoint inhibitors in OCSS are warranted regardless of HPV status.
Key words: Programmed death ligand-1 (PD-L1), Human papillomavirus (HPV), Oropharyngeal Neoplasms, Immune checkpoint inhibitor, Immune therapy

Introduction

Human papillomavirus (HPV) has been recognized as a cause of a subset of head and neck squamous cell carcinomas (HNSCC) [1]. HPV-associated HNSCC (HPV-HNSCC) arises most commonly in the oropharynx and the incidence of HPV-related oropharyngeal squamous cell carcinoma (OSCC) (HPV-OSCC) has been increasing despite a decline in tobacco consumption and contrary to a diminishing incidence of cancers at other head and neck sites. In the United States, approximately 40%-80% of OSCCs are caused by HPV and the underlying mechanism is believed to be chronic persistent infection leading to carcinogenesis [2]. Compared with HNSCC associated with smoking and/or alcohol, patients with HPV-OSCC tend to be younger, of a higher socioeconomic status, have a favorable natural history, and respond better to treatment [3]. Although at least 15 types of HPV are thought to have oncogenic potential, the vast majority of HPV-OSCCs are associated with HPV type 16, the same type that leads to HPV-associated anogenital cancers [4]. HPV preferentially targets the highly specialized reticulated epithelium in the lymphoid tissue of the tonsils and the tongue base. HPV integrates its DNA genome into the host cell nucleus, leading to expression of the oncoproteins E6 and E7. The E6 protein induces substantial loss of p53 activity, whereas E7 binds and inactivates the retinoblastoma proteins, which are highly immunogenic and would be expected to induce an antitumor immune response [5].

In HNSCC, various mechanisms have been proposed for immune escape including down regulation of tumor antigen presentation, aberrant regulation of the signal transducer and activator of transcription family, release of immunosuppressive cytokines, and dysregulation of immune checkpoint receptors [6]. Tumor infiltrating lymphocytes (TILs) show high expression of co-inhibitory receptors such as cytotoxic T lymphocyte–associated antigen 4 and programmed cell death 1 (PD-1), so-called immune checkpoints. A persistent high level of PD-1 expression on antigen-presented CD8(+) cytotoxic T lymphocytes leads to “T cell exhaustion,” characterized by impaired effector function and persistent expression of inhibitory receptors. Programmed cell death-ligand 1 (PD-L1), also known as B7-H1, is a surface glycoprotein that induces T-cell anergy or apoptosis by binding to PD-1 on T lymphocytes [7]. Clinical trials have reported that inhibition of the PD-1:PD-L1 interaction with antibodies specific for PD-1 or PD-L1 has promising antitumor efficacy in patients with various malignancies including melanoma, non-small cell lung cancer (NSCLC), and HNSCC [8-10].

Recent studies reported that the PD-1:PD-L1 axis is highly related to HPV-positive rather than HPV-negative HNSCC [11,12]. PD-1 is expressed on effector T cells in both HPV-positive and -negative tumors, however the level of expression appears to be increased in HPV-positive HNSCC, suggesting that PD-1 expression on cytotoxic T cells is relevant and may play an important role, particularly in HPV-OSCC [11,12]. However, the clinical relevance of PD-L1 expression in OSCC remains unclear. We therefore examined PD-L1 expression on tumor cells in HPV-positive and -negative oropharyngeal cancer and analyzed its association with clinicopathologic characteristics and its prognostic relevance.

Materials and Methods

1. Patients

Patients who met the following criteria were recruited: oropharyngeal cancer arising from tonsil, soft palate, posterior wall of oropharynx, and base of tongue; squamous cell carcinoma; curative intent radiation therapy, concurrent chemoradiation therapy (CCRT), or surgery; no evidence of distant metastasis; available medical records and sufficient tumor tissue for immunohistochemical (IHC) staining of PD-L1 and p16. Formalin-fixed paraffin-embedded (FFPE) tissues from a diagnostic biopsy or surgical specimen were retrieved from the Department of Pathology. Baseline clinicopathologic characteristics including age, sex, smoking history, TNM stage at diagnosis, curative modality, and clinical follow-up data were collected retrospectively from the database at Samsung Medical Center. The study protocol and all related materials were approved by the Institutional Review Board of the institution.

2. HPV expression and p16 IHC

An HPV-positive tumor was defined by specific staining of tumor cells for p16 expression. Strong correlation between overexpression of p16 and HPV expression has been reported in several studies [13]. Tumor p16 expression was evaluated by IHC analysis using a mouse monoclonal antibody (CINtec) and visualized using an immunostainer (Ventana XT, Ventana, Tucson, AZ) and Ultraview Universal DAB Detection Kit (Ventana) [14]. Positive p16 expression was defined as diffuse nuclear and cytoplasmic staining in 70% or more of the tumor cells as determined by a pathologist (Y.H.K.) [14].

3. PD-L1 expression by IHC

PD-L1 expression was evaluated by IHC using the monoclonal anti-human B7-H1 antibody (clone 5H1, a non-commercial mAb kindly provided by Dr. Lieping Chen’s laboratory) as previously described [15]. Briefly, FFPE tumor sections were cut at 4 μm and then routinely deparaffinized and rehydrated in xylene and graded ethanol solutions. Antigen retrieval was performed in Tris-EDTA buffer. Sections were washed and incubated for 5 minutes in wash buffer (Dako #S3006, Dako, Glostrup, Denmark), and then placed on the Autostainer Plus (Dako) and subjected to the following protocol using a CSA II kit (Dako #K1497). First, the activity of endogenous peroxidase was blocked with endogenous blocking solution, and then the section was washed with wash buffer and incubated for 60 minutes with monoclonal antihuman B7-H1 (clone 5H1) diluted 1:1,000 with antibody diluent containing background reducing components. After washing, the sections were incubated with biotin-conjugated rat anti-mouse IgG1 secondary antibody at a 1:500 dilution. Reaction products were visualized by incubation in 3, 3'-diaminobenzidine for 2 minutes and the slides were counterstained with hematoxylin.

A pathologist (M.H.) who was blinded to the patients’ clinicopathologic information assessed the expression of PD-L1. PD-L1 positivity was defined as membrane staining in ≥ 20% of tumor cells. PD-L1 expression on tumor cells was evaluated using the intensity score and proportion score. The intensity of staining was evaluated according to the following scale: 0, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining. Because most prognostic factors are considered as dichotomized and discontinuous variables, a cutoff point was selected to give the optimal separation between low risk and high risk for overall survival (OS). We initially set several cutoff points for selection of the best value, and then selected 20% staining as the appropriate cutoff value regardless of intensity score.

4. Statistical analysis

The relationship between PD-L1 expression and other patient characteristics, including p16 expression, was evaluated using analysis of variance tests for continuous variables and Pearson’s chi-square tests for discrete variables. Association of PD-L1 expression with survival of patients with OSCC was also evaluated. OS was defined as the time from the date of diagnosis to death as a result of any cause or the last follow-up if the patient was alive. Progression-free survival (PFS) was defined as the time from the initial date of treatment to disease progression or the last follow-up if the patient had not progressed. Survival curves were generated using the Kaplan-Meier method, and the difference between the curves according to PD-L1 status was evaluated using the log-rank test. The Cox proportional hazard model was used to assess hazard ratios (HRs) of prognostic factors for OS. All factors showing statistical significance in univariate analyses or clinical significance were included in the multivariate analysis. All p-values are two sided, and a level of 5% was considered statistically significant. All statistical analyses were performed using SPSS ver. 21 (IBM Co., Armonk, NY).

Results

1. Patient characteristics

From October 2002 to September 2013, of a total of 198 patients with OSCC who underwent screening, 133 patients (67%) were eligible for the current study. Patient characteristics are described in Table 1. The median age of patients was 57.5 years (range, 35 to 80 years), 120 patients (90%) were male, and 51 (38%) were never smokers. Seventy-nine patients (59%) had stage IV disease at diagnosis, and the most common site of tumor origin was tonsil (78%), followed by soft palate (7%) and base of tongue (3%). Ninety-two patients (69%) underwent curative intent surgery, and 35 (26%) underwent CCRT.

2. Prevalence of PD-L1 expression on tumor cell membrane

Overall, PD-L1 expression was positive in 90 patients (68%) and negative in 43 (32%). PD-L1 expression according to proportion was scored using various cutoff values as absent (no staining) in 15 patients (11%), ≥ 10% in 116 (87%), ≥ 20% in 90 (68%), ≥ 50% in 51 (38%), and ≥ 80% in 23 (17%). PD-L1 expression according to intensity was scored as absent in 15 patients (11%), weak in 55 (41%), moderate in 43 (32%), and strong in 20 (15%). The proportion score of PD-L1 expression showed correlation with the intensity score (Pearson coefficiency r=0.451, p=0.01).

3. Association of PD-L1 expression and clinical characteristics

No statistically significant association was observed between PD-L1 expression and age, sex, location of tumor origin, or stage (Table 1). In addition, smoking history was not associated with PD-L1 expression in the tumor cell membrane (p=0.343).

4. Association of PD-L1 and p16 expression

A total of 89 patients (67%) were positive for p16. Patients with p16 positivity had more advanced nodal (N2-3; 62% vs. 48%, p=0.002) and tumor stage (III-IV; 94% vs. 73%, p=0.001),and were more likely to have tonsillar cancer (89% vs. 57%, p < 0.001) than those negative for p16 (Table 2). p16 expression was more frequently observed in tonsillar cancer compared with other oropharyngeal cancers (79/104 [76%] vs. 10/29 [34%], p < 0.001).

No significant correlation was observed between PD-L1 and p16 expression (63/89 [71%] for p16-positive and 27/44 [61%] for p16-negative tumors, respectively, p=0.274). In analysis with several cutoff values of PD-L1 expression including proportion score and intensity score, no correlation was observed between PD-L1 and p16 expression. When the analysis was restricted to patients with tonsillar cancer, no association was found between PD-L1 expression and p16 expression (57/79 [72%] for p16 positive vs. 18/25 [72%] for p16 negative, p=0.988).

5. Association of PD-L1 expression and survival

Over a median follow-up period of 44 months (range, 2.8 to 119.3 months), 15 PD-L1–positive patients (17%) and nine PD-L1–negative patients (21%) died. The 3-year OS was 85% for PD-L1–positive and 87% for PD-L1–negative disease. Median PFS and OS have not yet been reached in the entire cohort. Results of Kaplan-Meier analysis showed no significant difference in PFS and OS between PD-L1–positive and PD-L1–negative patients (p=0.519 and p=0.625, respectively) (Fig. 1A and B). In analysis with several cutoff values of PD-L1 expression including proportion score and intensity score, we found no significant difference in PFS and OS. The patients were further divided into p16-positive and p16-negative groups. Even though p16-positive patients had more advanced stage, they tended to show a more favorable PFS,but without statistical significance (p=0.091) (Fig. 2A and B). In the p16-positive subgroup, patients with PD-L1 expression had longer PFS than PD-L1–negative patients (p=0.049), but no significant difference in OS was observed (p=0.165) (Fig. 1C and D). In the p16-negative subgroup, PD-L1 expression was not associated with OS or PFS (p=0.356 and p=0.206, respectively) (Fig. 1E and F).

To determine the prognostic value of PD-L1 expression for OS, univariate and multivariate analyses were performed using the Cox regression model (Table 3). Old age (HR, 2.834; 95% confidence interval [CI], 1.206 to 6.660; p=0.017) and advanced T stage (T1-2 vs. T3-4; HR, 5.806; 95% CI, 2.430 to 13.868; p < 0.001) remained independent factors for poor prognosis, but PD-L1 expression did not affect OS regardless of HPV status.

Discussion

HNSCC is recognized as an immunosuppressive disease [16]. In a clinical trial, immunotherapy targeting the PD-1:PD-L1 axis yielded an objective response in a subset of individuals with HNSCC [10] and a recent study suggested correlation of PD-L1 expression in tumors with response to PD-1 targeted therapy [9]. Taking these findings together, it is worth investigating the prognostic role of PD-L1 expression. PD-L1 expression in the tumor has shown correlation with both favorable and unfavorable outcomes in various malignancies. Several studies have examined PD-L1 expression in HNSCC [11,12,17]; however, the clinicopathologic characteristics associated with PD-L1 expression remain largely unknown.

In the study by Cho et al. [18], PD-L1 expression was positive in 39 of 43 OSCCs (91%) and did not show correlation with clinicopathologic factors or OS. Ukpo et al. [17] reported that PD-L1 was expressed in 84 of 181 patients (46%) with oropharyngeal cancer and no association was observed between PD-L1 expression and gender, smoking history, stage, or other clinical parameters; however, there was an association between PD-L1 expression and distant metastasis (p=0.03). In the current study, 68% of OSCC patients showed PD-L1 expression, consistent with previous results [17,18]. However, expression of PD-L1 in tumor cells did not show correlation with any clinicopathologic features, including PFS and OS.

Other studies in nasopharyngeal cancer have reported conflicting results; one study reported an association of PD-L1 expression with TNM stage, while the other showed no correlation with any of the clinicopathologic parameters examined [19,20]. These conflicting results in various tumors may be attributed in part to the lack of uniformity in assays, including intra- or inter-observer variability of IHC, lack of standardized antibodies for determining PD-L1 expression, and various cutoff values for defining positive expression.

Another possible explanation is that PD-L1 signaling not only down regulates antitumor effector T cell immunity, but also interacts with the innate and adaptive immune response [21]. In a recent study, tumors with PD-L1 positivity at baseline showed a significant decrease in PD-L1 expression at disease progression, whereas tumors with PD-L1 negativity at baseline showed a significant increase in PD-L1 expression at disease progression, irrespective of chemotherapeutic regimens [22]. This study suggests the possibility of dynamic changes in PD-L1 expression. Moreover, differences in PD-L1 expression between tumor cells and tumor infiltrating inflammatory cells may be a possible cause of conflicting results. Bhandari and Siva [23] reported that higher PD-L1 expression in tumor cells was associated with advanced disease in patients with urothelial carcinoma and also showed correlation with poor survival. Another study reported that PD-L1 in urothelial carcinoma cells was not predictive for OS, but positive PD-L1 expression in tumor infiltrating mononuclear cells showed significant association with longer survival [24]. Therefore, the prognostic value of PD-L1 expression should be further explored.

HPV-HNSCC arises from deep crypts within the lymphoid tissue of the tonsil and base of the tongue and the majority of cases can be distinguished from HPV-negative HNSCC by the characteristic infiltration of lymphocytes in the stroma and tumor nests [25]. There is substantial evidence that HNSCC is an immunosuppressive disease, particularly HPV-positive HNSCC, and recent preclinical and clinical studies suggest that the PD-1:PD-L1 pathway is highly related to the pathogenesis of HPV-HNSCC [11,12,16]. However, it is unclear whether the PD-1:PD-L1 pathway plays a greater role in HPV-positive HNSCC compared to HPV-negative HNSCC.

In the current study, 67% of patients had p16-positive disease indicating HPV-OSCC, consistent with previous reports [4]. We found that HPV-OSCC was associated with more advanced N stage, a trend for less advanced T stage, and occurrence at a relatively young age. In addition, there was a trend toward favorable PFS in p16-positive patients compared to p16-negative patients despite the more advanced stage in the p16-positive group. In this study, the small difference in survival benefit in the HPV-positive OSCC group may be attributed to the limited sample size and relatively few events in the entire cohort.

We found no association between PD-L1 expression and HPV status. Similarly, Badoual et al. [11] reported that 33 of 64 HNSCCs (51.5%) expressed a significant level of PD-L1 in tumor cells, but no correlation was observed between PD-L1 expression and HPV status (HPV positive vs. negative, 62.5% vs. 40%, p=0.08). However, HPV-HNSCC was more heavily infiltrated by CD8+ T cells (p=0.01) and PD-1+CD4+ T cells (p=0.045), and the total number of PD-1+CD4+ and PD-1+CD8+ T cells (p=0.045) was higher than that in HPVnegative HNSCC. Ukpo et al. [17] reported the presence of PD-L1 expression in 68 of 138 HPV mRNA-positive patients (49%) compared with 14 of 41 HPV mRNA-negative patients (34%) (odds ratio, 3.4; p=0.08). In contrast, Lyford-Pike et al. [12] reported that PD-L1 was expressed at a much higher level in HPV-positive tumors compared with HPV-negative tumors (14/20 [70%] vs. 2/7 [29%]).

A recent study reported that PD-L1 expression in tumors showed correlation with improved efficacy of the immune checkpoint inhibitor anti–PD-1 antibody in NSCLC [9]. The predictive role of PD-L1 expression in HNSCC patients treated with immune checkpoint inhibitors should be further explored. In addition, given the high expression of PD-L1 regardless of HPV status, clinical studies with anti–PD-1 or anti–PD-L1 antibody are warranted in both HPV-positive and HPV-negative patients. Identification of predictive biomarkers related to efficacy of immune checkpoint inhibitors, in combination with HPV status, might provide further clinical benefit to patients with HNSCC.

Our study has several limitations. First, 33% of patients diagnosed with OSCC were not included in the current analysis because of lack of tumor tissue, indicating a potential selection bias. Second, even though a relatively large cohort was analyzed, compared to previous studies, because of the favorable prognosis of OSCC only a few events occurred in the entire cohort. This might limit the power of the study to determine the prognostic role of PD-L1 expression. Consequently, it is not yet certain that PD-L1 expression truly has no prognostic role or it is just a reflection of lack of statistical power. Third, we did not explore PD-L1 expression in TILs. Finally, the inherent nature of a retrospective study makes it impossible to explore any dynamic changes in PD-L1 expression.

Conclusion

In conclusion, we showed that PD-L1 was highly expressed in OSCC, but there was no correlation between PD-L1 expression and HPV status. Further large prospective studies are required to determine the role of PD-L1 expression as a prognostic or predictive biomarker, and clinical studies of immune checkpoint inhibitors in OSCC are warranted regardless of HPV status.

NOTES

Conflict of interest relevant to this article was not reported.

Fig. 1.

Kaplan-Meier curves of overall survival (OS) and progression-free survival (PFS) according to programmed cell death-ligand 1 (PD-L1) expression status in patients with oropharyngeal squamous cell carcinoma. The p-value for difference between the two curves was determined using the log-rank test. (A) OS for overall population. (B) PFS for overall population. (C) OS for the p16-positive group. (D) PFS for the p16-positive group. (E) OS for the p16-negative group. (F) PFS for the p16-negative group.

Fig. 2.

Kaplan-Meier curves of overall survival (OS) (A) and progression-free survival (PFS) (B) according to p16 expression status in patients with oropharyngeal squamous cell carcinoma.

Table 1.

Clinicopathologic characteristics of patients with oropharyngeal squamous cell carcinoma and their relationship with PD-L1 expression

Characteristic	No. of patients (n=133)	PD-L1 (+) (n=90)	PD-L1 (–) (n=43)	p-value
Age (yr)	57.5 (35.4-80.1)	57.3 (35.4-72.8)	57.7 (42.2-80.1)	0.203
≥ 65 yr	30 (22.6)	17 (18.9)	13 (30.2)	0.108
Sex
Male	120 (90.2)	78 (86.7)	42 (97.7)	0.060
Female	13 (9.8)	12 (13.3)	1 (2.3)
Smoking
Never smoker	51 (38.3)	37 (41.1)	14 (32.6)	0.343
Ever smoker	82 (61.7)	53 (58.9)	29 (67.4)
Location
Tonsil	104 (78.2)	75 (83.3)	29 (67.4)	0.197
Base of tongue	4 (3.0)	2 (2.2)	2 (4.7)
Soft palate	9 (6.8)	4 (4.4)	5 (11.6)
Oropharynx, NOS	16 (12.0)	9 (10.0)	7 (16.3)
T stage
T1	33 (24.8)	18 (20.0)	15 (34.9)	0.247
T2	74 (55.6)	53 (58.9)	21 (48.8)
T3	15 (11.3)	10 (11.1)	5 (11.6)
T4	11 (8.3)	9 (10.0)	2 (4.7)
N stage
N0	22 (16.5)	14 (15.6)	8 (18.6)	0.137
N1	35 (26.3)	19 (21.1)	16 (37.2)
N2	68 (51.1)	50 (55.6)	18 (41.9)
N3	8 (6.0)	7 (7.8)	1 (2.3)
AJCC stage
I	8 (6.0)	3 (3.3)	5 (11.6)	0.100
II	9 (6.8)	6 (6.7)	3 (7.0)
III	37 (27.8)	22 (24.4)	15 (34.9)
IV	79 (59.4)	59 (65.6)	20 (46.5)
HPV p16 status
Positive	89 (66.9)	63 (70)	26 (60.5)	0.274
Negative	44 (33.1)	27 (30)	17 (39.5)
First-line curative modality
Operation	92 (69.2)	60 (66.7)	32 (74.4)	0.280
CCRT	35 (26.3)	27 (30.0)	8 (18.6)
RT	6 (4.5)	3 (3.3)	3 (7.0)

Values are presented as median (range) or number (%). PD-L1, programmed cell death-ligand 1; NOS, not otherwise specified; AJCC, American Joint Committee on Cancer; HPV, human papillomavirus; CCRT, concurrent chemoradiation therapy; RT, radiation therapy.

Table 2.

Clinicopathologic characteristics of patients with oropharyngeal squamous cell carcinoma and their relationship with HPV expression

Characteristic	p16 (–) (n=44)	p16 (+) (n=89)	p-value
Age (yr)	59.0 (35.4-80.1)	54.9 (41.4-73.5)	0.100
≥ 65 yr	14 (31.8)	16 (18.0)	0.072
Sex
Male	42 (95.5)	78 (87.6)	0.130
Female	2 (4.5)	11 (12.4)
Smoking
Never smoker	14 (31.8)	37 (41.6)	0.276
Ever smoker	30 (68.2)	52 (58.4)
Location
Tonsil	25 (56.8)	79 (88.8)	< 0.001
Base of tongue	3 (6.8)	1 (1.1)
Soft palate	8 (18.2)	1 (1.1)
Oropharynx, NOS	8 (18.2)	8 (9.0)
T stage
T1	9 (20.5)	24 (27.0)	0.220
T2	22 (50.0)	52 (58.4)
T3	8 (18.2)	7 (7.9)
T4	5 (11.4)	6 (6.7)
N stage
N0	15 (34.1)	7 (7.9)	0.002
N1	8 (18.2)	27 (30.3)
N2	19 (43.2)	49 (55.1)
N3	2 (4.5)	6 (6.7)
AJCC stage
I	4 (9.1)	4 (4.5)	0.001
II	8 (18.2)	1 (1.1)
III	9 (20.5)	28 (31.5)
IV	23 (52.3)	56 (62.9)
PD-L1 status
Positive	27 (61.4)	63 (70.8)	0.274
Negative	17 (38.6)	26 (29.2)
First-line curative modality
CCRT	7 (15.9)	28 (31.5)	0.155
Operation	35 (79.5)	57 (64.0)
RT	2 (4.5)	4 (4.5)

Values are presented as median (range) or number (%). HPV, human papillomavirus; NOS, not otherwise specified; AJCC, American Joint Committee on Cancer; PD-L1, programmed cell death-ligand 1; CCRT, concurrent chemoradiation therapy; RT, radiation therapy.

Table 3.

Univariate and multivariate analysis to assess the association of clinical parameters with survival

Characteristic	Univariate analysis		Multivariate analysis
Characteristic	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (< 65 yr vs. ≥ 65 yr)	2.531 (1.105-5.793)	0.028	2.834 (1.206-6.660)	0.017
Sex (male vs. female)	0.042 (0.001-10.401)	0.278	-	-
Smoking (never vs. ever)	2.198 (0.904-5.349)	0.083	2.270 (0.913-5.644)	0.078
Tumor location (tonsil vs. others)	1.798 (0.766-4.220)	0.17	-	-
T stage (T1-2 vs. T3-4)	6.311 (2.656-14.991)	< 0.001	5.806 (2.430-13.868)	< 0.001
N stage (N0-1 vs. N2-3)	2.532 (1.004-6.384)	0.049	2.118 (0.836-5.365)	0.114
HPV status (no vs. yes)	0.595 (0.266-1.328)	0.205	-	-
PD-L1: cutoff 5% (no vs. yes)	0.698 (0.238-2.046)	0.513	-	-
PD-L1: cutoff 20% (no vs. yes)	0.814 (0.356-1.863)	0.626	-	-
First-line curative modality (CCRT/RT vs. operation)	1.365 (0.506-3.681)	0.539	-	-

HR, hazard ratio; CI, confidence interval; HPV, human papillomavirus; PD-L1, programmed cell death-ligand 1; CCRT, concurrent chemo-radiation therapy; RT, radiation therapy.

REFERENCES

1. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709–20. Article PubMed
2. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11:781–9. Article PubMed PMC
3. Richards L. Human papillomavirus: a powerful predictor of survival in patients with oropharyngeal cancer. Nat Rev Clin Oncol. 2010;7:481.Article PubMed
4. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14:467–75. Article PubMed
5. Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene. 2002;21:1510–7. Article PubMed
6. Bauman JE, Ferris RL. Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer. 2014;120:624–32. Article PubMed PMC
7. Flies DB, Sandler BJ, Sznol M, Chen L. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med. 2011;84:409–21. PubMed PMC
8. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32. Article PubMed
9. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28. Article PubMed
10. Seiwert TY, Burtness B, Weiss J, Gluck I, Eder JP, Pai SI, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. J Clin Oncol. 2014;32 Suppl:Abstr 6011.Article
11. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013;73:128–38. Article PubMed
12. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733–41. Article PubMed PMC
13. Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol. 2009;27:6213–21. Article PubMed
14. Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res. 2003;9:6469–75. PubMed
15. Dong H, Zhu G, Tamada K, Flies DB, van Deursen JM, Chen L. B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity. 2004;20:327–36. Article PubMed
16. Gildener-Leapman N, Ferris RL, Bauman JE. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol. 2013;49:1089–96. Article PubMed PMC
17. Ukpo OC, Thorstad WL, Lewis JS Jr. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2013;7:113–21. Article PubMed PMC
18. Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011;47:1148–53. Article PubMed
19. Zhang F, Liu Z, Cui Y, Wang G, Cao P. The clinical significance of the expression of costimulatory molecule PD-L1 in nasopharyngeal carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2008;22:408–10.
20. Hsu MC, Hsiao JR, Chang KC, Wu YH, Su IJ, Jin YT, et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol. 2010;23:1393–403. Article PubMed
21. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800. Article PubMed
22. Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, et al. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients. Clin Cancer Res. 2015;21:3140–8. Article PubMed
23. Bhandari M, Siva S. Re: Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy R. H. Thompson, S. A. Boorjian, C. M. Lohse, B. C. Leibovich, E. D. Kwon, J. C. Cheville and M. L. Blute J Urol 2008; 179: 468-473. J Urol. 2008;180:1568–9. Article
24. Bellmunt J, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015;26:812–7. Article PubMed
25. Westra WH. The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol. 2009;3:78–81. Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

A bibliometric analysis of immune response in oral cancer
Rongrong Zhang, Runying Guo, Yuqi Xin, Qingkun Jiang, Jiaxuan Qiu
Discover Oncology.2025;[Epub] CrossRef
HPV frequency in oral cavity and oropharynx cancers and its association with immune checkpoint inhibitors
Hayriye Tatlı Doğan, Mustafa Tahtacı
Türk Tıp Dergisi.2025; 10(1): 1. CrossRef
Treatment Outcomes of Squamous Cell Carcinoma of the Soft Palate and the Prognostic Significance of HPV/p16 Status
Meng‐hua Li, Xing Zhang, Feng‐jiao Li, Xian‐lu Gao, Shi‐da Yan, Qiao‐hong Lin, Xi‐yuan Li, Jian Meng, Ying Zhang, Shi‐ting Zhang, Shu‐wei Chen, Ming Song
Head & Neck.2025;[Epub] CrossRef
Prognostic role of PD-L1 expression in head and neck squamous cell carcinoma: An institutional experience from India
Pooja Sharma Kala, Naveen Thapliyal, Bhawna Pant, Nitin Sharma, Hari Shankar Pandey
Pathology - Research and Practice.2024; 254: 155133. CrossRef
Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures – Principes généraux de traitement
Béatrix Barry, Gilles Dolivet, Florian Clatot, Florence Huguet, Cyril Abdeddaim, Bertrand Baujat, Nicolas Blanchard, Gilles Calais, Xavier Carrat, Anne Chatellier, Florence Coste, Didier Cupissol, Philippe Cuvelier, Erwan De Mones Del Pujol, Sophie Deneuv
Bulletin du Cancer.2024; 111(4): 393. CrossRef
PD-L1 expression in head and neck squamous cell carcinoma and its clinical significance: A prospective observational study from a tertiary care centre
Sindhu Kilaru, Soumya Surath Panda, Lalatendu Moharana, Debahuti Mohapatra, Satya Sundar G. Mohapatra, Adyakinkar Panda, Spoorthy Kolluri, Suma Devaraj, Ananya Kabi, Bharat Das, Ghanashyam Biswas
Journal of Cancer Research and Therapeutics.2024; 20(1): 46. CrossRef
Histologic and Genomic Analysis of Conjunctival SCC in African and American Cohorts Reveal UV Light and HPV Signatures and High Tumor Mutation Burden
Frederico O. Gleber-Netto, Priyadharsini Nagarajan, Oded Sagiv, Curtis R. Pickering, Neil Gross, Jing Ning, Melisachew M. Yeshi, Yonas Mitku, Michael T. Tetzlaff, Bita Esmaeli
Investigative Opthalmology & Visual Science.2024; 65(4): 24. CrossRef
Considerable interlaboratory variation in PD‐L1 positivity for head and neck squamous cell carcinoma in the Netherlands— A nationwide evaluation study
Maaike Anna Hempenius, Bregje M Koomen, Ivette A G Deckers, Sjoukje F Oosting, Stefan M Willems, Bert van der Vegt
Histopathology.2024; 85(1): 133. CrossRef
The Role of Estrogen and Estrogen Receptors in Head and Neck Tumors
Jacqueline-Katrin Kranjčević, Josipa Čonkaš, Petar Ozretić
Cancers.2024; 16(8): 1575. CrossRef
PD-L1 Expression and Its Association With p16 in Head and Neck Squamous Cell Carcinoma in Southwestern Uganda
Rita Nabulya, Raymond Atwine, Brian Ssenkumba, Yekosani Mitala, Jamilah Nabukenya
Pathology and Laboratory Medicine International.2024; Volume 16: 1. CrossRef
High‐risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects
Irene Lo Cigno, Federica Calati, Carlo Girone, Marta Catozzo, Marisa Gariglio
Journal of Medical Virology.2024;[Epub] CrossRef
PD-L1 immunohistochemical expression considering HPV status in oropharyngeal squamous cell carcinoma
Raíssa Soares dos ANJOS, Marianne de Vasconcelos CARVALHO, Rayanna Thayse Florêncio COSTA, Belmiro Cavalcanti do Egito VASCONCELOS, Sandra Lúcia Dantas MORAES, Eduardo Piza PELLIZZER
Brazilian Oral Research.2024;[Epub] CrossRef
PD-1 and PD-L1 Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers
Katarzyna Malinowska, Andrzej Kowalski, Anna Merecz-Sadowska, Milena Paprocka-Zjawiona, Przemysław Sitarek, Tomasz Kowalczyk, Hanna Zielińska-Bliźniewska
Journal of Clinical Medicine.2023; 12(5): 2033. CrossRef
Immunotherapy in oral cancer: Review
Despoina Papaioannou, Spyridoula Petsali, Alida Ndreou, Fani Akritidou, Vasileios Zisis, Dimitrios Kavvadas, Athanasios Poulopoulos, Sofia Karachrysafi, Dimitrios Andreadis
Balkan Journal of Dental Medicine.2023; 27(3): 129. CrossRef
Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma
Amandeep Kaur, Kristine Kuchta, William Watkin, Megan Sullivan, Lin Liu, Pouya Jamshidi, Nick Campbell, Bruce Brockstein, Ajit Paintal
Archives of Pathology & Laboratory Medicine.2023; 147(4): 442. CrossRef
Expression of immune checkpoint protein in oral squamous cell carcinoma and its clinicopathological correlation: A tertiary care center cross-sectional study
Sonal Ratnakar, Madhu Kumar, Malti K. Maurya, Sumaira Qayoom, Mala Sagar, Suresh Babu, Vijay Kumar
Journal of Oral and Maxillofacial Pathology.2023; 27(3): 597. CrossRef
Commentary on “Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma”
Juan Francisco Peña-Cardelles, José Ernesto Moro-Rodríguez, José Luís Cebrián-Carretero, José Juan Pozo-Kreilinger
Open Medicine.2022; 17(1): 227. CrossRef
Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis
Ramy R. Saleh, Jordan L. Scott, Nicholas Meti, Danielle Perlon, Rouhi Fazelzad, Alberto Ocana, Eitan Amir
Molecular Diagnosis & Therapy.2022; 26(2): 153. CrossRef
Immunotherapy for head and neck cancer: Present and future
Morena Fasano, Carminia Maria Della Corte, Raimondo Di Liello, Giuseppe Viscardi, Francesca Sparano, Maria Lucia Iacovino, Fernando Paragliola, Antonio Piccolo, Stefania Napolitano, Giulia Martini, Floriana Morgillo, Salvatore Cappabianca, Fortunato Ciard
Critical Reviews in Oncology/Hematology.2022; 174: 103679. CrossRef
Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma
Sebastian Blatt, Maximilian Krüger, Constantin Rump, Stefanie Zimmer, Keyvan Sagheb, Julian Künzel, Afsheen Raza
PLOS ONE.2022; 17(5): e0269136. CrossRef
Expression of PD-L1 is HPV/P16-independent in oral squamous cell carcinoma
Kit Kitichotkul, Nirush Lertprasertsuke, Sompid Kintarak, Surawut Pongsiriwet, Warit Powcharoen, Anak Iamaroon
Heliyon.2022; 8(10): e10667. CrossRef
Survival Outcomes of Complete Pulmonary Metastasectomy for Head and Neck Squamous Cell Carcinomas
Hiroaki Kuroda, Shin Koyama, Mingyon Mun, Jun Nakajima, Kazuhito Funai, Ichiro Yoshino, Yoshikane Yamauchi, Masafumi Kawamura
Cancer Management and Research.2022; Volume 14: 3095. CrossRef
Expression of PD-L1 is HPV/P16-Independent in Oral Squamous Cell Carcinoma
Kit Kitichotkul, Nirush Lertprasertsuke, Sompid Kintarak, Surawut Pongsiriwet, Warit Powcharoen, Anak Iamaroon
SSRN Electronic Journal .2022;[Epub] CrossRef
CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma
Songtao Zhang, Qiujie Yan, Song Wei, Xiaobo Feng, Miaomiao Xue, Lina Liu, Jili Cui, Yuanyuan Zhang
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2021; 132(2): 202. CrossRef
PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis
Yuan Qin, Jiaochen Luan, Xiang Zhou, Ying Li
Bioscience Reports.2021;[Epub] CrossRef
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
Parmida Sadat Pezeshki, Pouya Mahdavi Sharif, Nima Rezaei
Expert Opinion on Biological Therapy.2021; 21(12): 1575. CrossRef
PD-L1 TESTING AND IMMUNOTHERAPY SELECTION – EARLY LABORATORY EXPERIENCE AND ITS POTENTIAL ROLE IN HEAD AND NECK CANCER MANAGEMENT
Bancu Bancu, Richard Cowan, Anshuman Chaturvedi
Archive of Clinical Cases.2021; 8(1): 14. CrossRef
Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus
Huanhuan Wang, Qin Zhao, Yuyu Zhang, Qihe Zhang, Zhuangzhuang Zheng, Shiyu Liu, Zijing Liu, Lingbin Meng, Ying Xin, Xin Jiang
Frontiers in Immunology.2021;[Epub] CrossRef
The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis
Emily Clarke, Jesper Grau Eriksen, Sarah Barrett
Acta Oncologica.2021; 60(11): 1534. CrossRef
Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma
Alexander A. Strait, Rachel A. Woolaver, Spencer C. Hall, Christian D. Young, Sana D. Karam, Antonio Jimeno, Yan Lan, David Raben, Jing H. Wang, Xiao-Jing Wang
Communications Biology.2021;[Epub] CrossRef
Commentary on 'Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis' (He et al., (2020) Archives of Oral Biology, 114, 104717)
Juan Francisco Peña-Cardelles, José Ernesto Moro-Rodríguez, José Luís Cebrián-Carretero, José Juan Pozo-Kreilinger
Archives of Oral Biology.2021; 132: 105274. CrossRef
Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
Kimberly M. Burcher, Jeffrey W. Lantz, Elena Gavrila, Arianne Abreu, Jack T. Burcher, Andrew T. Faucheux, Amy Xie, Clayton Jackson, Alexander H. Song, Ryan T. Hughes, Thomas Lycan, Paul M. Bunch, Cristina M. Furdui, Umit Topaloglu, Ralph B. D’Agostino, We
Cancers.2021; 13(22): 5733. CrossRef
Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: A Meta-Analysis
Jerry Polesel, Anna Menegaldo, Giancarlo Tirelli, Vittorio Giacomarra, Roberto Guerrieri, Lorena Baboci, Mariateresa Casarotto, Valentina Lupato, Giuseppe Fanetti, Paolo Boscolo-Rizzo, Elisabetta Fratta
Frontiers in Oncology.2021;[Epub] CrossRef
Tumor Immunity and Immunotherapy for HPV-Related Cancers
Achraf A. Shamseddine, Bharat Burman, Nancy Y. Lee, Dmitriy Zamarin, Nadeem Riaz
Cancer Discovery.2021; 11(8): 1896. CrossRef
An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives
Daniel Lenouvel, Miguel Ángel González‐Moles, Asmae Talbaoui, Pablo Ramos‐García, Lucía González‐Ruiz, Isabel Ruiz‐Ávila, José Antonio Gil‐Montoya
Oral Diseases.2020; 26(3): 511. CrossRef
A treatise on endothelial biology and exosomes: homage to Theresa Maria Listowska Whiteside
N. Ludwig, M. T. Lotze
HNO.2020; 68(2): 71. CrossRef
PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva
Bastian Czogalla, Deborah Pham, Fabian Trillsch, Miriam Rottmann, Julia Gallwas, Alexander Burges, Sven Mahner, Thomas Kirchner, Udo Jeschke, Doris Mayr, Elisa Schmoeckel
Journal of Cancer Research and Clinical Oncology.2020; 146(3): 569. CrossRef
Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking
Jacob K. Lilja-Fischer, Jesper G. Eriksen, Jeanette B. Georgsen, Thao T. Vo, Stine R. Larsen, Jonathan Cheng, Michael Busch-Sørensen, Deepti Aurora-Garg, Torben Steiniche, Jens Overgaard
Acta Oncologica.2020; 59(6): 666. CrossRef
Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment
Lien Lippens, Mieke Van Bockstal, Emiel A. De Jaeghere, Philippe Tummers, Amin Makar, Sofie De Geyter, Koen Van de Vijver, An Hendrix, Katrien Vandecasteele, Hannelore Denys
International Journal of Cancer.2020; 147(2): 554. CrossRef
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
Victor C. Kok
Frontiers in Oncology.2020;[Epub] CrossRef
The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis
Hui Tang, Xiang Zhou, Yu Ye, Yi Zhou, Chengyu Wu, Yan Xu
Pathology - Research and Practice.2020; 216(1): 152768. CrossRef
Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis
Jing He, Xiao-Fang Chen, Ming-Gao Xu, Jing Zhao
Archives of Oral Biology.2020; 114: 104717. CrossRef
The role of transforming growth factor‐beta in immune suppression and chronic inflammation of squamous cell carcinomas
Alexander A. Strait, Xiao‐Jing Wang
Molecular Carcinogenesis.2020; 59(7): 745. CrossRef
The roles of programmed death ligand 1 in virus-associated cancers
Morvarid Golrokh Mofrad, Donya Taghizadeh Maleki, Ebrahim Faghihloo
Infection, Genetics and Evolution.2020; 84: 104368. CrossRef
Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma
Yong-Xin Cui, Xian-Shuang Su
Open Medicine.2020; 15(1): 292. CrossRef
The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma
Dominik Gurin, Marek Slavik, Marketa Hermanova, Iveta Selingerova, Tomas Kazda, Michal Hendrych, Tetiana Shatokhina, Marcela Vesela
Journal of Oral Pathology & Medicine.2020; 49(9): 886. CrossRef
PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma
Nora Wuerdemann, Sibel E. Gültekin, Katharina Pütz, Claus Wittekindt, Christian U. Huebbers, Shachi J. Sharma, Hans Eckel, Anna B. Schubotz, Stefan Gattenlöhner, Reinhard Büttner, Ernst-Jan Speel, Jens P. Klussmann, Steffen Wagner, Alexander Quaas
International Journal of Molecular Sciences.2020; 21(15): 5228. CrossRef
Evaluation of p16 in Epithelial Ovarian Cancer for a 10-Year Study in Northeast China: Significance of HPV in Correlation with PD-L1 Expression

Xinxin Yang, Qi You, Guodong Yao, Jingshu Geng, Rong Ma, Hongxue Meng
Cancer Management and Research.2020; Volume 12: 6747. CrossRef
Prevalence of high-risk human papillomavirus and its genotype distribution in head and neck squamous cell carcinomas
Yuil Kim, Young-Hoon Joo, Min-Sik Kim, Youn Soo Lee
Journal of Pathology and Translational Medicine.2020; 54(5): 411. CrossRef
The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
Xin-wei Qiao, Jian Jiang, Xin Pang, Mei-chang Huang, Ya-jie Tang, Xin-hua Liang, Ya-ling Tang
Frontiers in Immunology.2020;[Epub] CrossRef
Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma
Barbara Seliger, Chiara Massa, Bo Yang, Daniel Bethmann, Matthias Kappler, Alexander Walter Eckert, Claudia Wickenhauser
International Journal of Molecular Sciences.2020; 21(19): 7032. CrossRef
PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
D. Evrard, M. Hourseau, A. Couvelard, V. Paradis, H. Gauthier, E. Raymond, C. Halimi, B. Barry, S. Faivre
OncoImmunology.2020;[Epub] CrossRef
Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients
Atsumu Kouketsu, Ikuro Sato, Mariko Oikawa, Yoshinaka Shimizu, Hiroki Saito, Tetsu Takahashi, Hiroyuki Kumamoto
Journal of Cranio-Maxillofacial Surgery.2019; 47(1): 33. CrossRef
The value of immunotherapy in head and neck cancer
Paolo Manca, Luis E. Raez, Matthew Salzberg, Jorge Sanchez, Brian Hunis, Christian Rolfo
Expert Opinion on Biological Therapy.2019; 19(1): 35. CrossRef
Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route
Iacopo Panarese, Gabriella Aquino, Andrea Ronchi, Francesco Longo, Marco Montella, Immacolata Cozzolino, Giuseppe Roccuzzo, Giuseppe Colella, Michele Caraglia, Renato Franco
Expert Review of Anticancer Therapy.2019; 19(2): 105. CrossRef
The Double-Edged Sword—How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer
Hao-fan Wang, Sha-sha Wang, Ya-Jie Tang, Yu Chen, Min Zheng, Ya-ling Tang, Xin-hua Liang
Frontiers in Immunology.2019;[Epub] CrossRef
The protective role of carnosic acid in ischemic/reperfusion injury through regulation of autophagy under T2DM
Min Hu, Tianyu Li, Zixiang Bo, Feixiang Xiang
Experimental Biology and Medicine.2019; 244(7): 602. CrossRef
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva
Fabinshy Thangarajah, Bernd Morgenstern, Caroline Pahmeyer, Lars Mortimer Schiffmann, Julian Puppe, Peter Mallmann, Stefanie Hamacher, Reinhard Buettner, Christina Alidousty, Barbara Holz, Andreas H. Scheel, Anne Maria Schultheis
Journal of Cancer Research and Clinical Oncology.2019; 145(6): 1651. CrossRef
The emergence of long-term survivors in recurrent and metastatic squamous cell head and neck cancer
Florian Castet, Jesús Brenes, Miren Taberna, Ricard Mesía
Current Opinion in Oncology.2019; 31(3): 160. CrossRef
PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas
Giuseppe Riva, Giancarlo Pecorari, Matteo Biolatti, Sara Pautasso, Irene Lo Cigno, Massimiliano Garzaro, Valentina Dell’Oste, Santo Landolfo
Molecular Biology Reports.2019; 46(3): 3333. CrossRef
PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma
Priyadharsini Nagarajan, Christian El-Hadad, Stephen K. Gruschkus, Jing Ning, Courtney W. Hudgens, Oded Sagiv, Neil Gross, Michael T. Tetzlaff, Bita Esmaeli
Investigative Opthalmology & Visual Science.2019; 60(6): 2388. CrossRef
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma
Yui Hirata-Nozaki, Takayuki Ohkuri, Kenzo Ohara, Takumi Kumai, Marino Nagata, Shohei Harabuchi, Akemi Kosaka, Toshihiro Nagato, Kei Ishibashi, Kensuke Oikawa, Naoko Aoki, Mizuho Ohara, Yasuaki Harabuchi, Yuji Uno, Hidehiro Takei, Esteban Celis, Hiroya Kob
Journal of Translational Medicine.2019;[Epub] CrossRef
転移・再発頭頸部がんに対する分子標的薬と免疫チェックポイント阻害薬のエビデンス

Nippon Jibiinkoka Gakkai Kaiho.2019; 122(6): 848. CrossRef
Prognostic Value of Combined Programmed Cell Death 1 Ligand and p16 Expression Predicting Responsiveness to Radiotherapy in Patients with Oropharyngeal Squamous Cell Carcinoma
Minsu Kwon, Dae Hwan Kim, Ki Ju Cho, Youngchul Kim, Jin Pyeong Kim, Bae Kwon Jeong, Jong Sil Lee, Ji-Hyun Seo, Jung Je Park
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2019; 62(12): 712. CrossRef
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
Valerie Cristina, Ruth Gabriela Herrera-Gómez, Petr Szturz, Vittoria Espeli, Marco Siano
International Journal of Molecular Sciences.2019; 20(21): 5399. CrossRef
The expression of PD-L1 in salivary gland carcinomas
Domenic Vital, Kristian Ikenberg, Holger Moch, Matthias Rössle, Gerhard F. Huber
Scientific Reports.2019;[Epub] CrossRef
Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis
Yi-Qun Jia, Bo Yang, Li-Ling Wen, Wen-Xin Mu, Zhi Wang, Bin Cheng
Aging.2019; 11(2): 501. CrossRef
Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance
Nabil F. Saba, Zhuo Gerogia Chen, Missak Haigentz, Paolo Bossi, Alessandra Rinaldo, Juan P. Rodrigo, Antti A. Mäkitie, Robert P. Takes, Primoz Strojan, Jan B. Vermorken, Alfio Ferlito
Molecular Cancer Therapeutics.2019; 18(11): 1909. CrossRef
PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma
Juan C. de Vicente, Tania Rodríguez-Santamarta, Juan P. Rodrigo, Verónica Blanco-Lorenzo, Eva Allonca, Juana M. García-Pedrero
Cancer Epidemiology, Biomarkers & Prevention.2019; 28(3): 546. CrossRef
Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma
Theresa Scognamiglio, Yao-Tseng Chen
Head and Neck Pathology.2018; 12(2): 221. CrossRef
The Current State of Biological and Clinical Implications of Human Papillomavirus-Related Oropharyngeal Cancer
Shao Hui Huang, Brian O'Sullivan, John Waldron
Seminars in Radiation Oncology.2018; 28(1): 17. CrossRef
Implications of the tumor immune microenvironment for staging and therapeutics
Janis M Taube, Jérôme Galon, Lynette M Sholl, Scott J Rodig, Tricia R Cottrell, Nicolas A Giraldo, Alexander S Baras, Sanjay S Patel, Robert A Anders, David L Rimm, Ashley Cimino-Mathews
Modern Pathology.2018; 31(2): 214. CrossRef
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
Benjamin Solomon, Richard J. Young, Danny Rischin
Seminars in Cancer Biology.2018; 52: 228. CrossRef
Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs
Stefano Cavalieri, Licia Rivoltini, Cristiana Bergamini, Laura D. Locati, Lisa Licitra, Paolo Bossi
Cancer Treatment Reviews.2018; 65: 78. CrossRef
Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition
Mi Jung Kwon, Young-Soo Rho, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Ji-Young Choe, Eun Soo Kim, Bumjung Park, Mineui Hong, Kyueng-Whan Min
Human Pathology.2018; 80: 28. CrossRef
The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus–Associated Head and Neck Squamous Cell Carcinoma
Christine Kunkle, Flavia G Rosado
Archives of Pathology & Laboratory Medicine.2018; 142(6): 719. CrossRef
Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer
Hoi-Lam Ngan, Lan Wang, Kwok-Wai Lo, Vivian Wai Yan Lui
Cancers.2018; 10(7): 210. CrossRef
PD‐1 and PD‐L1 expression in HNSCC primary cancer and related lymph node metastasis – impact on clinical outcome
Sven Schneider, Lorenz Kadletz, Robert Wiebringhaus, Lukas Kenner, Edgar Selzer, Thorsten Füreder, Orsolya Rajky, Anna S Berghoff, Matthias Preusser, Gregor Heiduschka
Histopathology.2018; 73(4): 573. CrossRef
The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis
Wei-fa Yang, May C.M. Wong, Peter J. Thomson, Kar-Yan Li, Yu-xiong Su
Oral Oncology.2018; 86: 81. CrossRef
Prognostic value of PD -L1 expression in patients with primary solid tumors
Xiao Xiang, Peng-Cheng Yu, Di Long, Xiao-Li Liao, Sen Zhang, Xue-Mei You, Jian-Hong Zhong, Le-Qun Li
Oncotarget.2018; 9(4): 5058. CrossRef
Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy
Tatiana Lepikhova, Piia-Riitta Karhemo, Riku Louhimo, Bhagwan Yadav, Astrid Murumägi, Evgeny Kulesskiy, Mikko Kivento, Harri Sihto, Reidar Grénman, Stina M. Syrjänen, Olli Kallioniemi, Tero Aittokallio, Krister Wennerberg, Heikki Joensuu, Outi Monni
Molecular Cancer Therapeutics.2018; 17(9): 2060. CrossRef
Immune check point inhibitors for head and neck cancer
Naomi Kiyota
Toukeibu Gan.2018; 44(4): 336. CrossRef
Immune check point inhibitors for head and neck cancer and its proper management on utilizing head and neck cancer collaborative program
Naomi Kiyota
Journal of Japanese Society of Oral Oncology.2018; 30(4): 144. CrossRef
Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study
Matthias Troeltzsch, Timothy Woodlock, Alix Pianka, Sven Otto, Markus Troeltzsch, Michael Ehrenfeld, Thomas Knösel
Journal of Oral and Maxillofacial Surgery.2017; 75(5): 969. CrossRef
Actualités sur l’immunothérapie en pathologie des voies aérodigestives supérieures
Sophie Outh-Gauer, Christophe Le Tourneau, Chloé Broudin, Florian Scotte, Hélène Roussel, Stéphane Hans, Marion Mandavit, Eric Tartour, Cécile Badoual
Annales de Pathologie.2017; 37(1): 79. CrossRef
Overview of Sinonasal and Ventral Skull Base Malignancy Management
Peter F. Svider, Michael Setzen, Soly Baredes, James K. Liu, Jean Anderson Eloy
Otolaryngologic Clinics of North America.2017; 50(2): 205. CrossRef
PD-L1 expression and CD8+ infiltration shows heterogeneity in Juvenile Recurrent Respiratory Papillomatosis
Tingyu Liu, Max Greenberg, Carissa Wentland, Brandon Sepe, Sarah Bowe, Gillian Diercks, Tiffany Huynh, Mari Mino-Kenudson, Richard Schlegel, David Kodack, Cyril Benes, Jeffrey Engelman, Christopher Hartnick
International Journal of Pediatric Otorhinolaryngo.2017;[Epub] CrossRef
Programmed cell death ligand 1 as a biomarker in head and neck cancer
Sara I. Pai, William C. Faquin
Cancer Cytopathology.2017; 125(7): 529. CrossRef
Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck
Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, Wouter Huvenne, Jo Van Dorpe, Liesbeth Ferdinande, Sylvie Rottey
Oral Oncology.2017; 70: 34. CrossRef
Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years
Linnea Haeggblom, Torbjörn Ramqvist, Massimo Tommasino, Tina Dalianis, Anders Näsman
Papillomavirus Research.2017; 4: 1. CrossRef
The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
Panagiotis Balermpas, Franz Rödel, Mechthild Krause, Annett Linge, Fabian Lohaus, Michael Baumann, Inge Tinhofer, Volker Budach, Ali Sak, Martin Stuschke, Eleni Gkika, Anca-Ligia Grosu, Amir Abdollahi, Jürgen Debus, Stefan Stangl, Ute Ganswindt, Claus Bel
International Journal of Cancer.2017; 141(3): 594. CrossRef
Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis
Ji Li, Ping Wang, Youliang Xu, Jung Weon Lee
PLOS ONE.2017; 12(6): e0179536. CrossRef
Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients
Feng Yang-Chun, Cheng Zhen-Zhen, Huang Yan-Chun, Ma Xiu-Min
Medicine.2017; 96(25): e7270. CrossRef
Expressions of programmed death (PD)‐1 and PD‐1 ligand (PD‐L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status
Wen Yang, Yan‐Ping Lu, Yi‐Zhou Yang, Jia‐Rui Kang, Yi‐Duo Jin, Hong‐Wei Wang
Journal of Obstetrics and Gynaecology Research.2017; 43(10): 1602. CrossRef
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
Chiun Hsu, Se-Hoon Lee, Samuel Ejadi, Caroline Even, Roger B. Cohen, Christophe Le Tourneau, Janice M. Mehnert, Alain Algazi, Emilie M.J. van Brummelen, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Aaron R. Hansen
Journal of Clinical Oncology.2017; 35(36): 4050. CrossRef
Human papillomavirus-related oropharyngeal cancer
M. Taberna, M. Mena, M.A. Pavón, L. Alemany, M.L. Gillison, R. Mesía
Annals of Oncology.2017; 28(10): 2386. CrossRef
Circulating tumour cell PD-L1 test for head and neck cancers
Arutha Kulasinghe, Liz Kenny, Chamindie Punyadeera
Oral Oncology.2017; 75: 6. CrossRef
Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer
Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, Philippe Deron, Fréderic Duprez, Debby Laukens, Jo Van Dorpe, Liesbeth Ferdinande, Sylvie Rottey
Oncotarget.2017; 8(46): 80443. CrossRef
Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
Axel Lechner, Hans Schlößer, Sacha I. Rothschild, Martin Thelen, Sabrina Reuter, Peter Zentis, Alexander Shimabukuro-Vornhagen, Sebastian Theurich, Kerstin Wennhold, Maria Garcia-Marquez, Lars Tharun, Alexander Quaas, Astrid Schauss, Jörg Isensee, Tim Huc
Oncotarget.2017; 8(27): 44418. CrossRef
Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology
Thomas Hecking, Thore Thiesler, Cynthia Schiller, Jean-Marc Lunkenheimer, Tiyasha H. Ayub, Andrea Rohr, Mateja Condic, Mignon-Denise Keyver-Paik, Rolf Fimmers, Jutta Kirfel, Walther Kuhn, Glen Kristiansen, Kirsten Kübler
Oncotarget.2017; 8(54): 92890. CrossRef
Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data
Gustavo Dix Junqueira Pinto, Luciano de Souza Viana, Cristovam Scapulatempo Neto, Sérgio Vicente Serrano
Journal of Immunology Research.2016; 2016: 1. CrossRef
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
Marlon C. Rebelatto, Anita Midha, Amita Mistry, Constantine Sabalos, Nicole Schechter, Xia Li, Xiaoping Jin, Keith E. Steele, Paul B. Robbins, John A. Blake-Haskins, Jill Walker
Diagnostic Pathology.2016;[Epub] CrossRef
Current clinical immunotherapeutic approaches for head and neck cancer
Carolina Soto Chervin, Bruce Brockstein
F1000Research.2016; 5: 803. CrossRef
PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials
Angela M Hong, Ricardo E Vilain, Sarah Romanes, Jean Yang, Elizabeth Smith, Deanna Jones, Richard A Scolyer, C Soon Lee, Mei Zhang, Barbara Rose
Oncotarget.2016; 7(47): 77010. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma

Cancer Res Treat. 2016;48(2):527-536. Published online September 15, 2015

DOI: https://doi.org/10.4143/crt.2015.249

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma

Fig. 1. Kaplan-Meier curves of overall survival (OS) and progression-free survival (PFS) according to programmed cell death-ligand 1 (PD-L1) expression status in patients with oropharyngeal squamous cell carcinoma. The p-value for difference between the two curves was determined using the log-rank test. (A) OS for overall population. (B) PFS for overall population. (C) OS for the p16-positive group. (D) PFS for the p16-positive group. (E) OS for the p16-negative group. (F) PFS for the p16-negative group.

Fig. 2. Kaplan-Meier curves of overall survival (OS) (A) and progression-free survival (PFS) (B) according to p16 expression status in patients with oropharyngeal squamous cell carcinoma.

Fig. 1.

Fig. 2.

Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma

Characteristic	No. of patients (n=133)	PD-L1 (+) (n=90)	PD-L1 (–) (n=43)	p-value
Age (yr)	57.5 (35.4-80.1)	57.3 (35.4-72.8)	57.7 (42.2-80.1)	0.203
≥ 65 yr	30 (22.6)	17 (18.9)	13 (30.2)	0.108
Sex
Male	120 (90.2)	78 (86.7)	42 (97.7)	0.060
Female	13 (9.8)	12 (13.3)	1 (2.3)
Smoking
Never smoker	51 (38.3)	37 (41.1)	14 (32.6)	0.343
Ever smoker	82 (61.7)	53 (58.9)	29 (67.4)
Location
Tonsil	104 (78.2)	75 (83.3)	29 (67.4)	0.197
Base of tongue	4 (3.0)	2 (2.2)	2 (4.7)
Soft palate	9 (6.8)	4 (4.4)	5 (11.6)
Oropharynx, NOS	16 (12.0)	9 (10.0)	7 (16.3)
T stage
T1	33 (24.8)	18 (20.0)	15 (34.9)	0.247
T2	74 (55.6)	53 (58.9)	21 (48.8)
T3	15 (11.3)	10 (11.1)	5 (11.6)
T4	11 (8.3)	9 (10.0)	2 (4.7)
N stage
N0	22 (16.5)	14 (15.6)	8 (18.6)	0.137
N1	35 (26.3)	19 (21.1)	16 (37.2)
N2	68 (51.1)	50 (55.6)	18 (41.9)
N3	8 (6.0)	7 (7.8)	1 (2.3)
AJCC stage
I	8 (6.0)	3 (3.3)	5 (11.6)	0.100
II	9 (6.8)	6 (6.7)	3 (7.0)
III	37 (27.8)	22 (24.4)	15 (34.9)
IV	79 (59.4)	59 (65.6)	20 (46.5)
HPV p16 status
Positive	89 (66.9)	63 (70)	26 (60.5)	0.274
Negative	44 (33.1)	27 (30)	17 (39.5)
First-line curative modality
Operation	92 (69.2)	60 (66.7)	32 (74.4)	0.280
CCRT	35 (26.3)	27 (30.0)	8 (18.6)
RT	6 (4.5)	3 (3.3)	3 (7.0)

Characteristic	p16 (–) (n=44)	p16 (+) (n=89)	p-value
Age (yr)	59.0 (35.4-80.1)	54.9 (41.4-73.5)	0.100
≥ 65 yr	14 (31.8)	16 (18.0)	0.072
Sex
Male	42 (95.5)	78 (87.6)	0.130
Female	2 (4.5)	11 (12.4)
Smoking
Never smoker	14 (31.8)	37 (41.6)	0.276
Ever smoker	30 (68.2)	52 (58.4)
Location
Tonsil	25 (56.8)	79 (88.8)	< 0.001
Base of tongue	3 (6.8)	1 (1.1)
Soft palate	8 (18.2)	1 (1.1)
Oropharynx, NOS	8 (18.2)	8 (9.0)
T stage
T1	9 (20.5)	24 (27.0)	0.220
T2	22 (50.0)	52 (58.4)
T3	8 (18.2)	7 (7.9)
T4	5 (11.4)	6 (6.7)
N stage
N0	15 (34.1)	7 (7.9)	0.002
N1	8 (18.2)	27 (30.3)
N2	19 (43.2)	49 (55.1)
N3	2 (4.5)	6 (6.7)
AJCC stage
I	4 (9.1)	4 (4.5)	0.001
II	8 (18.2)	1 (1.1)
III	9 (20.5)	28 (31.5)
IV	23 (52.3)	56 (62.9)
PD-L1 status
Positive	27 (61.4)	63 (70.8)	0.274
Negative	17 (38.6)	26 (29.2)
First-line curative modality
CCRT	7 (15.9)	28 (31.5)	0.155
Operation	35 (79.5)	57 (64.0)
RT	2 (4.5)	4 (4.5)

Characteristic	Univariate analysis		Multivariate analysis
Characteristic	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (< 65 yr vs. ≥ 65 yr)	2.531 (1.105-5.793)	0.028	2.834 (1.206-6.660)	0.017
Sex (male vs. female)	0.042 (0.001-10.401)	0.278	-	-
Smoking (never vs. ever)	2.198 (0.904-5.349)	0.083	2.270 (0.913-5.644)	0.078
Tumor location (tonsil vs. others)	1.798 (0.766-4.220)	0.17	-	-
T stage (T1-2 vs. T3-4)	6.311 (2.656-14.991)	< 0.001	5.806 (2.430-13.868)	< 0.001
N stage (N0-1 vs. N2-3)	2.532 (1.004-6.384)	0.049	2.118 (0.836-5.365)	0.114
HPV status (no vs. yes)	0.595 (0.266-1.328)	0.205	-	-
PD-L1: cutoff 5% (no vs. yes)	0.698 (0.238-2.046)	0.513	-	-
PD-L1: cutoff 20% (no vs. yes)	0.814 (0.356-1.863)	0.626	-	-
First-line curative modality (CCRT/RT vs. operation)	1.365 (0.506-3.681)	0.539	-	-

Table 1. Clinicopathologic characteristics of patients with oropharyngeal squamous cell carcinoma and their relationship with PD-L1 expression

Table 2. Clinicopathologic characteristics of patients with oropharyngeal squamous cell carcinoma and their relationship with HPV expression

Table 3. Univariate and multivariate analysis to assess the association of clinical parameters with survival

HR, hazard ratio; CI, confidence interval; HPV, human papillomavirus; PD-L1, programmed cell death-ligand 1; CCRT, concurrent chemo-radiation therapy; RT, radiation therapy.